ClinicalTrials.gg
RecruitingNCT07401173Updated Apr 9, 2026

DeepComp for Prediction of Gastric Cancer Postoperative Complications (DeepComp-Prospective)

An observational study in Gastric Cancer (Diagnosis) and Postoperative Complications, sponsored by Qun Zhao. Recruiting at 1 site in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-04-09.

Sponsored by Qun Zhao · Observational

How we know

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as recruiting.
  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,187 studies in Stomach Neoplasms with a site in China — 483 open to participants now, 560 under way, 50 of them phase 3. Stomach Neoplasms · China.

Planned enrollment
113th of 303
500 · median 300
Started
2026
with 95 others
Observational
303 of 1,187
132 open now
Primary completion
2026-05
later than 231 of 559 live
Registered
1,095th of 1,187
by date

Among the 1,187 studies in Stomach Neoplasms with a site in China, this one is the 113th largest by planned enrollment of the 303 observational ones that give a count, is one of 96 that started in 2026, is one of 303 observational ones, reaches primary completion later than 231 of the 559 other live ones, and was the 1,095th registered.

Stomach Neoplasms

3,407 studies on the registry are indexed under Stomach Neoplasms; 994 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

483 of the 1,187 studies in Stomach Neoplasms with a site in China are open now. Recruiting first, the newest first:

478 more — sign in →

All 483 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 375 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 27 take children under 18; 70 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,187 studies in Stomach Neoplasms with a site in China, or all of them as a file.
02

Study summary

Gastric cancer is a leading cause of cancer-related mortality, and radical surgery remains the primary treatment. However, postoperative complications are common and can significantly impact patient recovery and quality of life. Currently, doctors lack precise tools to accurately predict which patients are at high risk for developing severe complications before surgery.

This study aims to validate a novel artificial intelligence (AI) model called "DeepComp." The DeepComp model integrates clinical data with advanced radiomic features derived from routine preoperative CT scans. Specifically, it analyzes both the tumor characteristics and the patient's body composition (including skeletal muscle and fat distribution) to assess physiological reserve.

In this prospective, multicenter observational study, researchers will enroll patients scheduled for gastric cancer surgery across five medical centers. The DeepComp model will be used to predict the risk of moderate-to-severe postoperative complications (Clavien-Dindo grade II or higher). These predictions will then be compared with the actual clinical outcomes observed 30 days after surgery. The goal is to determine the accuracy and reliability of the DeepComp model in a real-world clinical setting, potentially providing a powerful tool for personalized surgical risk assessment.

03

Conditions studied

  • Gastric Cancer (Diagnosis)
  • Postoperative Complications
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients diagnosed with potentially resectable gastric cancer who are admitted to the participating centers for surgical treatment.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Age ≥ 18 years.

confirmed gastric adenocarcinoma.

Scheduled for elective radical gastrectomy (open, laparoscopic, or robotic) with curative intent.

Standard preoperative contrast-enhanced abdominal CT scans (venous phase) performed within 14 days prior to surgery.

Willingness to sign .

Exclusion criteria

Exclusion Criteria:

Emergency surgery due to perforation, obstruction, or massive bleeding.

Intraoperative findings of distant (Stage IV) or unresectable disease preventing R0 resection.

Concurrent or previous malignant tumors within the last 5 years (except gastric cancer).

Pregnancy or lactation.

Severe metallic artifacts on CT images preventing radiomic analysis.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Target follow-up
30 Days
Patient registry
Yes

Groups and cohorts

  • Gastric Cancer Surgery Cohort

    Patients diagnosed with gastric cancer who are scheduled to undergo radical gastrectomy (open, laparoscopic, or robotic). All participants will receive standard preoperative contrast-enhanced CT scans. The DeepComp AI model will be applied to these scans to predict the risk of postoperative complications.

06

What researchers measure

Primary outcomes

  1. Incidence of Major Postoperative Complications (Clavien-Dindo Grade ≥ II)

    Postoperative complications will be graded according to the Clavien-Dindo classification system. Major complications are defined as Grade II or higher, which require pharmacological treatment, surgical/endoscopic/radiological intervention, or life-threatening complications (including death). The occurrence of these events will be recorded and compared with the model's preoperative predictions.

    Time frame: Postoperative 30 days

  2. Human-AI Collaborative Diagnostic Performance in Gastric Cancer Surgery: Accuracy and Observer Agreement

    In a subset of 120 randomly selected gastric cancer surgery patients, ten surgeons of varying experience levels (Junior \<5 years, n=4; Intermediate 5-10 years, n=3; Senior ≥10 years, n=3) will first independently assess postoperative complication risk using blinded preoperative data. Subsequently, they will receive predictions from the DeepComp AI model and update their assessments.

    Time frame: From preoperative assessment through 30 days post-surgery

Secondary outcomes

  1. Predictive Performance of the DeepComp Model (AUC)

    The discrimination performance of the DeepComp model in predicting major postoperative complications will be evaluated using the Area Under the Receiver Operating Characteristic Curve (AUC). Sensitivity, specificity, positive predictive value, and negative predictive value will also be calculated.

    Time frame: Postoperative 30 days

  2. Length of Hospital Stay

    Defined as the number of days from surgery to discharge.

    Time frame: Up to 30 days

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for May 2026, 2 months after the start.

Of 324 non-industry observational studies under Stomach Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 171. This study's planned 2 months is below that.

Counting every sponsor, half of 367 studies reached it within 54 months; a quarter within 29 and three quarters within 119.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2026
First posted
Feb 10, 2026
StartActual
Mar 1, 2026
Primary completionEst.
May 1, 2026
CompletionEst.
May 1, 2026
Last update
Apr 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07401173
Lead sponsor
Qun Zhao
Responsible party
Qun Zhao (Professor, Hebei Medical University) — Sponsor-investigator
First posted
Feb 10, 2026
Start date
Mar 1, 2026
Primary completion
May 1, 2026 (estimated)
Completion
May 1, 2026 (estimated)
Last update
Apr 9, 2026

Study contacts

Ping'an Ding, PhD
Contact
ding_ping_an@hebmu.edu.cn
+8631186095363
Qun Zhao, PhD
Contact
zhaoqun@hebmu.edu.cn
031186095363
Qun Zhao
principal investigator · th

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion